Shares of CombiMatrix (NASDAQ:CBMX) rocked high after the largest study favoring CMA was published

A molecular diagnostic company, CombiMatrix Corporation (NASDAQ: CBMX [FREE stock trend Analysis]) is carrying out DNA-based testing services which helps in diagnosis of cancer and developmental disorders. According to the company, a study that is published in a leading journal in relation to diagnosis of genetic prenatal and genetic evaluation of stillbirths supports chromosomal microarray analysis, popularly known as CMA, more than traditional karyotyping one.

The recent edition of New England journal of Medicine has published two big studies that show the biggest nose to nose comparative study that was done weighing CMA directly against traditional karyotyping. Both the studies wrapped up finding that CMA has the capability to identifying genetic abnormalities that are clinically significant as well in both the assessments, that of stillbirths as well as prenatal diagnostic background, as compared to traditional karyotyping.

Ronald Wapner, M.D., is one of the most important medical professionals in the country working in the matter of reproductive genetics. Wapner is Vice Chairman at Columbia College of Physicians and Surgeons of Research and university Professor of Gynecology and Obstetrics and in Columbia University Medical Center and New York Presbyterian Hospital, he is the director. He is also the main author of the study conducted on prenatal diagnosis and co-author of the study that was carried out on stillbirths. Wapner has even demanded and justified to revolutionize karyotyping, which failed to established customary concern for these tests with CMA.

Despite of the fact that Wapner understands that the transition from karyotyping to CMA would be done gradually as the staff along with the physicians and patients have to be trained and well-informed about how to use it, the choice is clear from the two studies. According to a statement published via the New York Presbyterian and Columbia University Medical Center earlier this year, Wapner says that no one will prefer going on with the standard method if the result is only a part of the answer.

4,406 women were enrolled in the two studies, one of which was for Prenatal Diagnosis. It was observed that microarray analysis was possible only in 4,340 of the fetal samples, which is 98.8 percent. The second study was for genetic abnormalities after stillbirth and this included analysis of 532 stillbirths. The conclusion of this study was that microarray analysis is more liable than the karyotype analysis to get the genetic diagnosis done.

Moreover, the funding for both the studies was done by the Eunice Kennedy Shriver national institute of child health and human development, which is part of NIH (National Institutes of Health). Shares of CombiMatrix Corp (NASDAQ:CBMX) were up by 336.55% to close at $8.60.

About the Author

Alison Simpson is an Business and general assignment reporter. Alison Simpson covers financial markets and Wall Street, concentrating on developments affecting individual investors and their portfolios. Alison graduated from Trinity College in Hartford, Conn., and later earned a master’s degree from Northwestern's Medill School of Journalism. Alison also covered congress for Defense News and providing regular coverage of the budget debate on Capitol Hill and its implications for national security.

Leave A Response